{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:35Z","timestamp":1790796935732,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>New prophylactics for migraine, targeting calcitonin gene\u2010related peptide (CGRP), have recently emerged. Real\u2010world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real\u2010world setting, in order to determine which patients may be considered responders in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All erenumab\u2010treated patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a0100) completed a time\u2010locked daily electronic diary, and an automated algorithm was used to monitor treatment response. Monthly migraine days (MMD), non\u2010migrainous headache days, days of acute medication use (MAMD), well\u2010being and coping with pain were assessed for a 6\u2010month period. The primary outcome was reduction in MMD compared to baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The numbers of MMD and MAMD decreased in all months, in both episodic and chronic migraine patients, compared to baseline (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001), while general well\u2010being (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001) and coping with pain (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001) also improved. Of all patients, 36% had an MMD reduction of \u226550% in \u22653\/6\u00a0months, and 6% had such a reduction in all 6\u00a0months. For a \u226530% MMD reduction, the figures were 60% and 24%, respectively. Almost 90% of patients with an average MMD reduction of \u226530% over the first 3\u00a0months had a sustained response in the last 3\u00a0months. In addition, 20% of patients without an initial response (average &lt;30%), had a delayed response (average \u226530%) in the last 3\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Erenumab was effective in migraine patients who were highly refractory to previous prophylactics. As a practical guideline, we propose that treatment be continued for at least 6\u00a0months and that patients with a \u226530% MMD reduction in at least half of the treatment period should be considered to be responders.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.15075","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T15:22:01Z","timestamp":1629732121000},"page":"4194-4203","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Treatment with the monoclonal calcitonin gene\u2010related peptide receptor antibody erenumab: A real\u2010life study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-8773","authenticated-orcid":false,"given":"Simone","family":"de Vries Lentsch","sequence":"first","affiliation":[{"name":"Department of Neurology Leiden University Medical Center Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E.","family":"Verhagen","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center Leiden The Netherlands"},{"name":"Division of Vascular Medicine and Pharmacology Department of Internal Medicine Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"van den Hoek","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology Department of Internal Medicine Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela M.","family":"Terwindt","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821662"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415583146"},{"key":"e_1_2_8_10_1","article-title":"E\u2010diary use in clinical headache practice: a prospective observational study","author":"Casteren D","year":"2021","journal-title":"Cephalalgia"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010000"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-014-0117-0"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010019"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"issue":"4","key":"e_1_2_8_15_1","first-page":"973","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein SD","year":"2015","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00417"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01151-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000313"},{"key":"e_1_2_8_24_1","first-page":"546","article-title":"Calcitonin gene\u2010related peptide action on intestinal circular muscle","volume":"256","author":"Holzer P","year":"1989","journal-title":"Am J Physiol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32952-6"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.15075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:07:06Z","timestamp":1692828426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/ene.15075"],"URL":"https:\/\/doi.org\/10.1111\/ene.15075","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"2021-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}